These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38810324)

  • 1. Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors.
    Liang R; Adams D; Roncolato F; Asghari R; Descallar J; Pal A; Chua W; Balakrishnar B
    Clin Genitourin Cancer; 2024 Aug; 22(4):102116. PubMed ID: 38810324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance with follow-up for patients with stage 1 testicular germ cell tumour.
    Cheung KT; Dat A; Wong P; Dowling C; Davis ID; Sengupta S
    ANZ J Surg; 2021 Jan; 91(1-2):184-186. PubMed ID: 32618092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance of males with stage 1 testicular germ cell tumours on an active surveillance protocol.
    Honeyball F; Murali-Ganesh R; Hruby G; Grimison P
    Intern Med J; 2015 Oct; 45(10):1081-4. PubMed ID: 26429219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review.
    Chakiryan NH; Dahmen A; Cucchiara V; Briganti A; Montorsi F; Salonia A; Spiess PE; Necchi A
    J Urol; 2021 Jun; 205(6):1569-1576. PubMed ID: 33617328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era.
    Yuasa T; Inoshita N; Tanaka H; Urakami S; Yamamoto S; Fujii Y; Masuda H; Fukui I; Ishikawa Y; Yonese J
    Int J Clin Oncol; 2015 Dec; 20(6):1198-202. PubMed ID: 25893862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy.
    Mazzone E; Mistretta FA; Knipper S; Tian Z; Palumbo C; Gandaglia G; Soulieres D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1153-e1162. PubMed ID: 31515197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer.
    Escudero-Ávila R; Rodríguez-Castaño JD; Osman I; Fernandez F; Medina R; Vargas B; Japón-Rodríguez M; Sancho P; Perez-Valderrama B; Praena-Fernández JM; Duran I
    Clin Transl Oncol; 2019 Jun; 21(6):796-804. PubMed ID: 30470992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
    Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
    World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Active surveillance for testicular tumors: adherence and safety.].
    Rico L; Blas L; Vitagliano G; Villasante N; Rios Pita H; Contreras P; Lopez FM; Ameri C
    Arch Esp Urol; 2021 May; 74(4):397-403. PubMed ID: 33942732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
    Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fosså SD; Germà-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondruš D; Rosti G; Stephenson AJ; Tandstad T
    Ann Oncol; 2015 May; 26(5):833-838. PubMed ID: 25378299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
    Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
    J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
    Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
    J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy.
    Kobayashi K; Saito T; Kitamura Y; Nobushita T; Kawasaki T; Hara N; Takahashi K
    Diagn Pathol; 2013 Apr; 8():57. PubMed ID: 23566361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
    Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
    Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.
    Daugaard G; Gundgaard MG; Mortensen MS; Agerbæk M; Holm NV; Rørth M; von der Maase H; Christensen IJ; Lauritsen J
    J Clin Oncol; 2014 Dec; 32(34):3817-23. PubMed ID: 25267754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional risk of relapse in patients with germ cell testicular tumors: personalizing surveillance in clinical stage 1 disease.
    Goldberg H; Madhur N; Hamilton RJ
    Curr Opin Urol; 2018 Sep; 28(5):454-460. PubMed ID: 29916845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
    Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
    BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of active surveillance of clinical stage I non-seminomatous germ cell tumors: sub-analysis of the multi-institutional nationwide case series of the Japanese Urological Association.
    Shinoda Y; Matsui Y; Fujimoto H;
    Jpn J Clin Oncol; 2018 Jun; 48(6):565-569. PubMed ID: 29672733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience.
    Ondrusova M; Waczulikova I; Lehotska V; Zeleny T; Ondrus D
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1015-e1019. PubMed ID: 28673797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.